Display options
Cite
Montalban-Bravo G, Takahashi K, Patel K, et al. Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms. Oncotarget. 2018;9(11):9714-9727doi: 10.18632/oncotarget.23882.
Montalban-Bravo, G., Takahashi, K., Patel, K., Wang, F., Xingzhi, S., Nogueras, G. M., Huang, X., Pierola, A. A., Jabbour, E., Colla, S., Gañan-Gomez, I., Borthakur, G., Daver, N., Estrov, Z., Kadia, T., Pemmaraju, N., Ravandi, F., Bueso-Ramos, C., Chamseddine, A., Konopleva, M., Zhang, J., Kantarjian, H., Futreal, A., & Garcia-Manero, G. (2018). Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms. Oncotarget, 9(11), 9714-9727. https://doi.org/10.18632/oncotarget.23882
Montalban-Bravo, Guillermo, et al. "Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms." Oncotarget vol. 9,11 (2018): 9714-9727. doi: https://doi.org/10.18632/oncotarget.23882
Montalban-Bravo G, Takahashi K, Patel K, Wang F, Xingzhi S, Nogueras GM, Huang X, Pierola AA, Jabbour E, Colla S, Gañan-Gomez I, Borthakur G, Daver N, Estrov Z, Kadia T, Pemmaraju N, Ravandi F, Bueso-Ramos C, Chamseddine A, Konopleva M, Zhang J, Kantarjian H, Futreal A, Garcia-Manero G. Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms. Oncotarget. 2018 Jan 03;9(11):9714-9727. doi: 10.18632/oncotarget.23882. eCollection 2018 Feb 09. PMID: 29515765; PMCID: PMC5839396.
Copy Download .nbib Format: NLM
Share it on

Oncotarget. 2018 Jan 03;9(11):9714-9727. doi: 10.18632/oncotarget.23882. eCollection 2018 Feb 09.

Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms.

Oncotarget

Guillermo Montalban-Bravo, Koichi Takahashi, Keyur Patel, Feng Wang, Song Xingzhi, Graciela M Nogueras, Xuelin Huang, Ana Alfonso Pierola, Elias Jabbour, Simona Colla, Irene Gañan-Gomez, Gautham Borthakur, Naval Daver, Zeev Estrov, Tapan Kadia, Naveen Pemmaraju, Farhad Ravandi, Carlos Bueso-Ramos, Ali Chamseddine, Marina Konopleva, Jianhua Zhang, Hagop Kantarjian, Andrew Futreal, Guillermo Garcia-Manero

Affiliations

  1. Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  2. Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  3. Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  4. Applied Cancer Science Institute, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  5. Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

PMID: 29515765 PMCID: PMC5839396 DOI: 10.18632/oncotarget.23882

Abstract

The prognostic and predictive value of sequencing analysis in myelodysplastic syndromes (MDS) has not been fully integrated into clinical practice. We performed whole exome sequencing (WES) of bone marrow samples from 83 patients with MDS and 31 with MDS/MPN identifying 218 driver mutations in 31 genes in 98 (86%) patients. A total of 65 (57%) patients received therapy with hypomethylating agents. By univariate analysis, mutations in

Keywords: chronic myelomonocytic leukemia; mutations; myelodysplastic syndromes; prognosis; response

Conflict of interest statement

CONFLICTS OF INTEREST The authors do not disclose any conflicts of interest.

References

  1. Leukemia. 2015 Apr;29(4):847-57 - PubMed
  2. Blood. 2006 Jul 15;108(2):419-25 - PubMed
  3. Br J Haematol. 2013 Mar;160(5):660-72 - PubMed
  4. Expert Rev Mol Diagn. 2016;16(4):461-72 - PubMed
  5. N Engl J Med. 2011 Jun 30;364(26):2496-506 - PubMed
  6. Stat Med. 1996 Feb 28;15(4):361-87 - PubMed
  7. Blood. 2013 Nov 21;122(22):3616-27; quiz 3699 - PubMed
  8. Blood Cancer J. 2015 Jan 23;5:e275 - PubMed
  9. J Hematol Oncol. 2015 May 08;8:45 - PubMed
  10. J Clin Oncol. 2011 Jun 20;29(18):2499-506 - PubMed
  11. Leukemia. 2016 Apr;30(4):906-13 - PubMed
  12. Leuk Res. 2016 Mar;42:7-12 - PubMed
  13. Blood. 2016 May 19;127(20):2391-405 - PubMed
  14. Blood. 2016 Sep 1;128(9):1246-59 - PubMed
  15. Am J Hematol. 2013 Feb;88(2):120-9 - PubMed
  16. Blood. 2015 Jan 15;125(3):422-3 - PubMed
  17. J Clin Oncol. 2013 Nov 1;31(31):3898-905 - PubMed
  18. Bioinformatics. 2016 Sep 1;32(17 ):2699-701 - PubMed
  19. Oncotarget. 2016 Mar 22;7(12 ):14172-87 - PubMed
  20. J Clin Oncol. 2012 Mar 10;30(8):820-9 - PubMed
  21. Cytogenet Genome Res. 2013;141(1):1-6 - PubMed
  22. Blood. 2014 Oct 23;124(17):2705-12 - PubMed
  23. Am J Hematol. 2013 Nov;88(11):E277-82 - PubMed
  24. Bioinformatics. 2009 Nov 1;25(21):2865-71 - PubMed
  25. N Engl J Med. 2016 Nov 24;375(21):2023-2036 - PubMed
  26. Leukemia. 2014 Feb;28(2):241-7 - PubMed
  27. Genome Res. 2015 Sep;25(9):1382-90 - PubMed
  28. Blood. 2015 Jan 15;125(3):499-503 - PubMed
  29. Blood. 2012 Sep 20;120(12):2454-65 - PubMed
  30. Leukemia. 2011 Jul;25(7):1147-52 - PubMed
  31. Blood. 1997 Mar 15;89(6):2079-88 - PubMed
  32. Exp Hematol Oncol. 2015 May 20;4:14 - PubMed
  33. Blood. 2015 Jul 9;126(2):233-41 - PubMed
  34. Leukemia. 2016 Nov;30(11):2214-2220 - PubMed
  35. J Clin Oncol. 2013 Mar 1;31(7):916-22 - PubMed
  36. Bioinformatics. 2009 Jul 15;25(14):1754-60 - PubMed
  37. Blood Cancer J. 2015 Jul 31;5:e333 - PubMed
  38. Blood. 2014 Sep 11;124(11):1790-8 - PubMed
  39. Nat Biotechnol. 2013 Mar;31(3):213-9 - PubMed
  40. Blood. 2012 Apr 12;119(15):3578-84 - PubMed

Publication Types